ICOS and neoplasm: Since high PRKCI expression is associated not only with elevated ERK signaling and high autophagy risk score, but also with lower activities of anti-tumors immune signaling pathways, targeting PKCι may not only inhibit oncogenic signaling, but also reactivate immune protective signaling, such as the T cell activation and survival promoted by the co-stimulatory iCOS and OX40 signaling pathways, and the activation of tumor-targeting NK cells [68].